Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

Genetics Institute Suspends Phase 2 Study of rhIL-12




 

PR Newswire (06/09/95)

On Friday, Genetics Institute, Inc. announced that it has suspended a Phase II clinical trial of recombinant human interleukin-12 (rhIL-12) due to reports that several patients had to be hospitalized after taking the experimental drug. The Phase II study for the treatment of advanced kidney cancer was undertaken in part on the basis of Phase I dosing studies of the drug in oncology and HIV. In those studies, rhIL-12 was well-tolerated over a wide range of biologically active doses. The Phase II study, however, used a different dosing schedule and dosage form than the Phase I studies. A total of 10 patients have been hospitalized and one has died. The company has notified the Food and Drug Administration of the suspension, and is conducting an investigation which will help determine the extent to which these events may have been caused by rhIL-12.



 


Copyright © 1995 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in June 12, 1995. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.